Recent evidence has also suggested that SGLT2 inhibition can augment the actions of GLP,31 and this mechanism may be important when considering any potential benefit to patients with NAFLD. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.